Breakthrough 3D Engineered Cancer Models Could Reduce Animal Testing
A 3D visualization of tumor evolution. Credit: nature video YouTube Channel
A world expert in Tissue Engineering and Regenerative Medicine (TERM) has been awarded a prestigious international prize from the Institution of Engineering and Technology (IET). The prize fund will be used to create reliable breakthrough 3D engineered functional cancer disease models that can help predict the efficacy of cancer drugs, avoiding unnecessary animal testing and some clinical trials.
Prof. Rui L. Reis, from the University of Minho in Portugal, is the winner of the £350,000 IET A F Harvey Engineering Research Prize. He was chosen from high-calibre candidates from across the world as a result of his outstanding contributions and decades of excellent research in the field of 3D tissue engineering for regenerative therapies and disease models. The funding will support a further five years of work with the aim of creating a unique tissue engineering platform to generate 3D cancer microenvironments. These can be used as functional disease models for screening cancer drugs that are under development by the pharmaceutical industry, as well as novel therapies that are being tested by the medical community.
Prof. Rui L. Reis, said: “Cancer has become the third most likely cause of death worldwide. One of the most serious obstacles facing scientists involved in the development and assessment of new anti-cancer drugs and therapies is the failure of preclinical cancer models being able to predict, in a reliable way, whether a given drug will have anti-cancer activity and acceptable toxicity in humans. Most animal models are not representative of human situations, and currently more than 70-80% of cancer research is based on 2D models which can’t accurately replicate the three dimensional properties of cancer cells such as tumours.”
“I am honoured to receive this award that is considered by many to be one of the major international engineering awards. It is also a privilege to be the first winner whose career is based in a country that is not English-speaking and not a scientific powerhouse. I trust that it will help my team and I to use our TERM unique expertise in order to move towards solving this situation, by means of creating novel breakthrough and reliable 3D engineered functional cancer disease models. This will help to predict the efficacy of novel cancer drugs and potential therapies, avoiding a range of unnecessary animal tests, and preclinical and clinical trials of doomed-to-fail new drugs, and it will for sure have an impact in the future of health care providing.”
Sir John O’Reilly, Chair of the IET’s Selection Committee for the Prize, said: “Prof. Rui L. Reis is awarded the A F Harvey Research Prize in recognition of his outstanding research achievements and publication records, in Tissue Engineering and Regenerative Medicine. Trialling the efficacy of new anti-cancer drugs remains one of the biggest challenges facing scientists today and his breakthrough research in the field of 3D engineering of functional cancer disease models could accelerate the screening of new drugs and the approval of new treatments.”
The IET’s A F Harvey Research Prize, worth £350,000, is named after Dr A F Harvey who bequeathed a generous sum of money to the IET for a trust fund to be set up in his name for the furtherance of scientific research into the fields of medical, microwave, laser or radar engineering.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE